🤖 AI Summary
Accurate benign-malignant differentiation of focal liver lesions (FLLs) on non-contrast CT (NCCT) remains challenging, and existing methods rely heavily on multiphase contrast-enhanced CT or MRI—limiting clinical applicability. Method: We propose PLUS, a plug-and-play enhancement framework that requires no backbone modification and seamlessly integrates with any 3D segmentation model. PLUS enables end-to-end malignancy classification solely from NCCT by jointly optimizing segmentation and classification tasks using large-scale real-world NCCT data. Crucially, it leverages precise 3D lesion segmentation to fuse local contextual features and explicitly model inter-lesion discriminative patterns. Results: Evaluated on 8,651 patient cases, PLUS achieves a 5.66% improvement in lesion-level F1 score, and boosts case-level F1 scores by 6.26% for malignant and 4.03% for benign cases—significantly enhancing the diagnostic utility of routine abdominal NCCT.
📝 Abstract
Focal liver lesions (FLL) are common clinical findings during physical examination. Early diagnosis and intervention of liver malignancies are crucial to improving patient survival. Although the current 3D segmentation paradigm can accurately detect lesions, it faces limitations in distinguishing between malignant and benign liver lesions, primarily due to its inability to differentiate subtle variations between different lesions. Furthermore, existing methods predominantly rely on specialized imaging modalities such as multi-phase contrast-enhanced CT and magnetic resonance imaging, whereas non-contrast CT (NCCT) is more prevalent in routine abdominal imaging. To address these limitations, we propose PLUS, a plug-and-play framework that enhances FLL analysis on NCCT images for arbitrary 3D segmentation models. In extensive experiments involving 8,651 patients, PLUS demonstrated a significant improvement with existing methods, improving the lesion-level F1 score by 5.66%, the malignant patient-level F1 score by 6.26%, and the benign patient-level F1 score by 4.03%. Our results demonstrate the potential of PLUS to improve malignant FLL screening using widely available NCCT imaging substantially.